Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement
June 04 2020 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions International Announces Positive
Preclinical and Clinical Evaluation of Nutritional
Supplement QuadraMune™,
Designed to Protect Against COVD-19
Company Submits Results of Clinical Trial for Publication in
Peer-Reviewed Medical Journal
OCEANSIDE, CA -- June
4, 2020 -- InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced
today
the
submission to an international medical journal the results of
pre-clinical and clinical evaluation of QuadraMune™ in
32
healthy volunteers between 18-65 years of age, lacking chronic or
active disease.
The study
comprised
of 4 groups
of
patients who received
QuadraMune™, or
placebo. Group 1 was placebo control, Group 2, received
2 capsules
per day,
group 3 received 4 capsules
per day, and group 4 received 8 capsules
per
day. The trial lasted 7 days. QuadraMune™ was provided
by Therapeutic Solutions International.
"To date, there are no
FDA cleared means of preventing COVID-19. Despite work being
performed at "Warp-Speed" towards
vaccine
development, these efforts are still believed to be months if not
years away" said Dr. James
Veltmeyer, Chief Medical Officer of Therapeutic Solutions
International and "Top Doctor" of San Diego in 2012, 2014, 2016,
2017, and 2019. "We aimed to perform a
series of experiments to assess preclinical and pilot clinical
feasibility of QuadraMune™ to address the issue
of immune stimulation while inhibiting inflammation.
The
current data strongly supports
that the combination of natural ingredients in QuadraMune™
possesses a synergistic effect at suppressing key components of
"Cytokine Storm", namely interleukin-6 and TNF-alpha. If
studies continue to support these conclusions, future use of
QuadraMune™ in conditions such as cancer inflammation and
rheumatoid arthritis will be considered."
The cytokine
interleukin-6 is considered a cornerstone of the inflammatory
response. Suppression of interleukin-6 for pathological
inflammation, such as in rheumatoid arthritis, is the basis of the
drug Actemra
(Tocilizumab).
Manufactured by Roche, this drug had sales of $2.4 billion dollars
last year
[1].
"In vivo
administration of QuadraMune™ was successful in stimulating markers
of immunity both at the
level of
the innate immune response, and adaptive immune
responses,"
said
Timothy Dixon, President, and CEO of Therapeutic Solutions
International. "Many approaches that
suppress inflammation also suppress immunity. In order to
have a fighting chance, any approach being developed for this
condition must induce both the suppression of
inflammation and
the
activation of immunity. These early data support this
statement."
The Company plans to
expand clinical trials to patients suffering from COVID-19 and/or
individuals at risk of COVID-19. A pre-publication
copy, of the submitted
manuscript, is available by
following this link: https://therapeuticsolutionsint.com/CV/JTRM-D-20-01014.pdf
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is at
www.therapeuticsolutionsint.com
and our
e-commerce is at www.youcanordernow.com and for additional
info on QuadraMune™
visit www.areyoucovidmune.com/covidmune/.
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
[1] https://www.fiercepharma.com/pharma-asia/china-turns-roche-arthritis-drug-actemra-against-covid-19-new-treatment-guidelines
Therapeutic Solutions
International, Inc.
ir@tsoimail.com
- Nutraceutical Product Appears to Stimulate Natural Killer
Cell Arm of Immune System
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024